Institute for Molecular Medicine Finland (FIMM) is an international research institute in Helsinki focusing on human genomics and personalized medicine. FIMM integrates molecular medicine research, technology center and biobanking infrastructures “under one roof” and thereby promotes translational research and adoption of personalized medicine in health care.
FIMM researchers are involved in several grand challenge projects, such as the impact of genome information from the Finnish population in personalized health and medical interventions, development of individualized cancer medicine, and novel diagnostics via imaging of tissue and cells.
The disease areas of interest for the 15 research groups cover cancer, cardiovascular disease, neurology, and viral infections. FIMM technology centre and biobanking infrastructures provide research services for local, national and international customers, including collaborations with companies. The infrastructures operated by FIMM are networked with European ESFRI infrastructures BBMRI, EATRIS, ELIXIR and EU Openscreen.
In 2012, FIMM had a staff of 185 and an annual budget of 14 million euros, with competitive external funding accounting for 70% of the budget. FIMM is part of the Nordic EMBL Partnership for Molecular Medicine, composed of the European Molecular Biology Laboratory (EMBL) and the centers for molecular medicine in Norway, Sweden and Denmark. At the national level, FIMM is a joint research institute of the University of Helsinki (primary host), the Hospital District of Helsinki and Uusimaa, the National Institute for Health and Welfare, and VTT Technical Research Centre of Finland.